Japan's Takeda to buy Nimbus' Psoriasis Drug for as much as $6 bln

Tokyo, Japan, December 13, 2022 (Reuters) -- Takeda Pharmaceutical will buy U.S.-based Nimbus Therapeutics' experimental psoriasis drug for up to $6 billion, the Japanese drugmaker said on Tuesday, as it looks to cut reliance on treatments facing loss of patents.

Read full article here.